Your browser doesn't support javascript.
loading
Montrer: 20 | 50 | 100
Résultats 1 - 1 de 1
Filtre
Ajouter des filtres








Gamme d'année
1.
Braz. j. med. biol. res ; 51(5): e6714, 2018. tab, graf
Article Dans Anglais | LILACS | ID: biblio-889083

Résumé

This study aimed to investigate the protective effect of salvinorin A on the cerebral pial artery after forebrain ischemia and explore related mechanisms. Thirty Sprague-Dawley rats received forebrain ischemia for 10 min. The dilation responses of the cerebral pial artery to hypercapnia and hypotension were assessed in rats before and 1 h after ischemia. The ischemia reperfusion (IR) control group received DMSO (1 µL/kg) immediately after ischemia. Two different doses of salvinorin A (10 and 20 µg/kg) were administered following the onset of reperfusion. The 5th, 6th, and 7th groups received salvinorin A (20 µg/kg) and LY294002 (10 µM), L-NAME (10 μM), or norbinaltorphimine (norBIN, 1 μM) after ischemia. The levels of cGMP in the cerebrospinal fluid (CSF) were also measured. The phosphorylation of AKT (p-AKT) was measured in the cerebral cortex by western blot at 24 h post-ischemia. Cell necrosis and apoptosis were examined by hematoxylin-eosin staining (HE) and TUNEL staining, respectively. The motor function of the rats was evaluated at 1, 2, and 5 days post-ischemia. The dilation responses of the cerebral pial artery were significantly impaired after ischemia and were preserved by salvinorin A treatment. In addition, salvinorin A significantly increased the levels of cGMP and p-AKT, suppressed cell necrosis and apoptosis of the cerebral cortex and improved the motor function of the rats. These effects were abolished by LY294002, L-NAME, and norBIN. Salvinorin A preserved cerebral pial artery autoregulation in response to hypercapnia and hypotension via the PI3K/AKT/cGMP pathway.


Sujets)
Animaux , Mâle , Rats , Artères cérébrales/effets des médicaments et des substances chimiques , Encéphalopathie ischémique/métabolisme , Phosphatidylinositol 3-kinases/métabolisme , Diterpènes de type clérodane/pharmacologie , Transduction du signal , Artères cérébrales/physiopathologie , Encéphalopathie ischémique/traitement médicamenteux , Morpholines/administration et posologie , 4H-1-Benzopyran-4-ones/administration et posologie , Rat Sprague-Dawley , GMP cyclique/liquide cérébrospinal , GMP cyclique/métabolisme , L-NAME , Diterpènes de type clérodane/antagonistes et inhibiteurs , Modèles animaux de maladie humaine , Naltrexone/administration et posologie , Naltrexone/analogues et dérivés
SÉLECTION CITATIONS
Détails de la recherche